Regulation of the 5′-flanking region of the human CYP27B1 gene in osteoblast cells

Molecular and Cellular Endocrinology

Volumn 311, Issue 1-2, 2009, Pages 55-61

  Turner, A G ^a   Dwivedi, P P ^b   Anderson, P H ^b   May, B K ^b   Morris, H A ^b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c HANSON INSTITUTE   (Australia)

Author keywords

CYP27B1; Osteoblasts; Promoter; Repression; Smad; Vitamin D

Indexed keywords

CALCITRIOL; CYTOCHROME P450; CYTOCHROME P450 27B1; SMAD PROTEIN; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG; CALCIDIOL 1 MONOOXYGENASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; BINDING SITE; CONTROLLED STUDY; DNA FLANKING REGION; ENZYME STRUCTURE; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENOME SIZE; KIDNEY CELL; NONHUMAN; OSTEOBLAST; PARACRINE SIGNALING; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; RAT; REPORTER GENE; VITAMIN METABOLISM; ANIMAL; DRUG EFFECT; ENHANCER REGION; ENZYMOLOGY; GENETICS; HUMAN; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; 5' FLANKING REGION; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR SEQUENCE DATA; OSTEOBLASTS; PROMOTER REGIONS, GENETIC; RATS; SEQUENCE DELETION; TRANSFORMING GROWTH FACTOR BETA;

EID: 69249221565     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.06.001     Document Type: Article

References (36)

1. Anderson P.H., May B.K., and Morris H.A. Vitamin D metabolism: new concepts and clinical implications. Clin. Biochem. Rev. 24 (2003) 13-26
2. Anderson P.H., O'Loughlin P.D., May B.K., and Morris H.A. Modulation of CYP27B1 and CYP24 mRNA expression in bone is independent of circulating 1,25(OH)2D3 levels. Bone 36 (2005) 654-662
3. Anderson P.H., Sawyer R.K., Moore A.J., May B.K., O'Loughlin P.D., and Morris H.A. Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model. J. Bone Miner. Res. 23 (2008) 1789-1797
4. Armbrecht H.J., Boltz M.A., and Hodam T.L. PTH increases renal 25(OH)D3-1alpha-hydroxylase (CYP1alpha) mRNA but not renal 1,25(OH)2D3 production in adult rats. Am. J. Physiol. Renal Physiol. 284 (2003) F1032-F1036
5. Armbrecht H.J., Hodam T.L., and Boltz M.A. Hormonal regulation of 25-hydroxyvitamin D3-1alpha-hydroxylase and 24-hydroxylase gene transcription in opossum kidney cells. Arch. Biochem. Biophys. 409 (2003) 298-304
6. Atkins G.J., Anderson P.H., Findlay D.M., Welldon K.J., Vincent C., Zannettino A.C., O'Loughlin P.D., and Morris H.A. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha, 25-dihydroxyvitamin D3. Bone 40 (2007) 1517-1528
7. Atkins G.J., Kostakis P., Pan B., Farrugia A., Gronthos S., Evdokiou A., Harrison K., Findlay D.M., and Zannettino A.C. RANKL expression is related to the differentiation state of human osteoblasts. J. Bone Miner. Res. 18 (2003) 1088-1098
8. Bahr A., Hankeln T., Fiedler T., Hegemann J., and Schmidt E.R. Molecular analysis of METTL1, a novel human methyltransferase-like gene with a high degree of phylogenetic conservation. Genomics 57 (1999) 424-428
9. Brenza H.L., Kimmel-Jehan C., Jehan F., Shinki T., Wakino S., Anazawa H., Suda T., and DeLuca H.F. Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 1387-1391
10. Dardenne O., Prud'homme J., Arabian A., Glorieux F.H., and St-Arnaud R. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 142 (2001) 3135-3141
11. DeLuca H.F., and Cantorna M.T. Vitamin D: its role and uses in immunology. FASEB J. 15 (2001) 2579-2585
12. Denissova N.G., and Liu F. Repression of endogenous Smad7 by Ski. J. Biol. Chem. 279 (2004) 28143-28148
13. Dusso A.S., Brown A.J., and Slatopolsky E. Vitamin D. Am. J. Physiol. Renal Physiol. 289 (2005) F8-28
14. Dwivedi P.P., Anderson P.H., Omdahl J.L., Grimes H.L., Morris H.A., and May B.K. Identification of growth factor independent-1 (GFI1) as a repressor of 25-hydroxyvitamin D 1-alpha hydroxylase (CYP27B1) gene expression in human prostate cancer cells. Endocr. Relat. Cancer 12 (2005) 351-365
15. Ebert R., Jovanovic M., Ulmer M., Schneider D., Meissner-Weigl J., Adamski J., and Jakob F. Down-regulation by nuclear factor kappaB of human 25-hydroxyvitamin D3 1alpha-hydroxylase promoter. Mol. Endocrinol. 18 (2004) 2440-2450
16. Gao X.H., Dwivedi P.P., Choe S., Alba F., Morris H.A., Omdahl J.L., and May B.K. Basal and parathyroid hormone induced expression of the human 25-hydroxyvitamin D 1alpha-hydroxylase gene promoter in kidney AOK-B50 cells: role of Sp1, Ets and CCAAT box protein binding sites. Int. J. Biochem. Cell Biol. 34 (2002) 921-930
17. Hendrix I., Anderson P., May B., and Morris H. Regulation of gene expression by the CYP27B1 promoter-study of a transgenic mouse model. J. Steroid Biochem. Mol. Biol. 89-90 (2004) 139-142
18. Hsu J.Y., Feldman D., McNeal J.E., and Peehl D.M. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 61 (2001) 2852-2856
19. Kong X.F., Zhu X.H., Pei Y.L., Jackson D.M., and Holick M.F. Molecular cloning, characterization, and promoter analysis of the human 25-hydroxyvitamin D3-1alpha-hydroxylase gene. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 6988-6993
20. Massague J., Seoane J., and Wotton D. Smad transcription factors. Genes Dev. 19 (2005) 2783-2810
21. Matsumoto K., Hashimoto K., Nishida Y., Hashiro M., and Yoshikawa K. Growth-inhibitory effects of 1,25-dihydroxyvitamin D3 on normal human keratinocytes cultured in serum-free medium. Biochem. Biophys. Res. Commun. 166 (1990) 916-923
22. Matsumoto T., Igarashi C., Takeuchi Y., Harada S., Kikuchi T., Yamato H., and Ogata E. Stimulation by 1,25-dihydroxyvitamin D3 of in vitro mineralization induced by osteoblast-like MC3T3-E1 cells. Bone 12 (1991) 27-32
23. Murayama A., Kim M.S., Yanagisawa J., Takeyama K., and Kato S. Transrepression by a liganded nuclear receptor via a bHLH activator through co-regulator switching. EMBO J. 23 (2004) 1598-1608
24. Murayama A., Takeyama K., Kitanaka S., Kodera Y., Kawaguchi Y., Hosoya T., and Kato S. Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha, 25(OH)2D3 in intact animals. Endocrinology 140 (1999) 2224-2231
25. Nagarajan R.P., Zhang J., Li W., and Chen Y. Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J. Biol. Chem. 274 (1999) 33412-33418
26. Nomura T., Khan M.M., Kaul S.C., Dong H.D., Wadhwa R., Colmenares C., Kohno I., and Ishii S. Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor. Genes Dev. 13 (1999) 412-423
27. Omdahl J.L., Morris H.A., and May B.K. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu. Rev. Nutr. 22 (2002) 139-166
28. Owen T.A., Aronow M.S., Barone L.M., Bettencourt B., Stein G.S., and Lian J.B. Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in normal rat osteoblast cultures. Endocrinology 128 (1991) 1496-1504
29. Panda D.K., Miao D., Tremblay M.L., Sirois J., Farookhi R., Hendy G.N., and Goltzman D. Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 7498-7503
30. Price P.A., and Baukol S.A. 1,25-Dihydroxyvitamin D3 increases synthesis of the vitamin K-dependent bone protein by osteosarcoma cells. J. Biol. Chem. 255 (1980) 11660-11663
31. Shinki T., Shimada H., Wakino S., Anazawa H., Hayashi M., Saruta T., DeLuca H.F., and Suda T. Cloning and expression of rat 25-hydroxyvitamin D3-1alpha-hydroxylase cDNA. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 12920-12925
32. Shteyer A., Gazit D., Passi-Even L., Bab I., Majeska R., Gronowicz G., Lurie A., and Rodan G. Formation of calcifying matrix by osteosarcoma cells in diffusion chambers in vivo. Calcif. Tissue Int. 39 (1986) 49-54
33. Turner A.G., Dwivedi P.P., May B.K., and Morris H.A. Regulation of the CYP27B1 5′-flanking region by transforming growth factor-beta in ROS 17/2.8 osteoblast-like cells. J. Steroid Biochem. Mol. Biol. 103 (2007) 322-325
34. Turner R.T., Puzas J.E., Forte M.D., Lester G.E., Gray T.K., Howard G.A., and Baylink D.J. In vitro synthesis of 1 alpha,25-dihydroxycholecalciferol and 24,25-dihydroxycholecalciferol by isolated calvarial cells. Proc. Natl. Acad. Sci. U.S.A. 77 (1980) 5720-5724
35. van Driel M., Koedam M., Buurman C.J., Hewison M., Chiba H., Uitterlinden A.G., Pols H.A., and van Leeuwen J.P. Evidence for auto/paracrine actions of vitamin D in bone: 1{alpha}-hydroxylase expression and activity in human bone cells. FASEB J. 20 (2006) 2417-2419
36. Vary C.P., Li V., Raouf A., Kitching R., Kola I., Franceschi C., Venanzoni M., and Seth A. Involvement of Ets transcription factors and targets in osteoblast differentiation and matrix mineralization. Exp. Cell Res. 257 (2000) 213-222